These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6966394)

  • 1. [Prevention of methotrexate toxicity during intensive neoplasm treatment].
    Orzechowska-Juzwenko K
    Pol Tyg Lek; 1980 Feb; 35(5):169-71. PubMed ID: 6966394
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
    Fujimoto T
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Folic acid prevention of the adverse effects of methotrexate].
    Szabó G; Mezei G
    Fogorv Sz; 1984 Mar; 77(3):71-3. PubMed ID: 6608458
    [No Abstract]   [Full Text] [Related]  

  • 5. Searching for magic bullets: early approaches to chemotherapy-antifolates, methotrexate--the Bruce F. Cain memorial award lecture.
    Jukes TH
    Cancer Res; 1987 Nov; 47(21):5528-36. PubMed ID: 3311354
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure of leucovorin "rescue" in methotrexate treatment of psoriasis.
    Cipriano AP; Selsky LM; Bertino JR
    Arch Dermatol; 1970 Jun; 101(6):651-2. PubMed ID: 5310496
    [No Abstract]   [Full Text] [Related]  

  • 7. Antidotal effects of calcium folinate against high-dose methotrexate-induced damages to mouse matured oocytes.
    Tian N; Ma W
    Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):101-103. PubMed ID: 31833536
    [No Abstract]   [Full Text] [Related]  

  • 8. Folate supplementation during methotrexate therapy for patients with psoriasis.
    Strober BE; Menon K
    J Am Acad Dermatol; 2005 Oct; 53(4):652-9. PubMed ID: 16198787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of folinic acid (leucovorin) on cytotoxic and cytogenetic effects of methotrexate].
    Pieńkowska K; Koziorowska J
    Folia Med Cracov; 1986; 27(3-4):239-44. PubMed ID: 3494651
    [No Abstract]   [Full Text] [Related]  

  • 10. Methotrexate: clinical pharmacology, current status and therapeutic guidelines.
    Bleyer WA
    Cancer Treat Rev; 1977 Jun; 4(2):87-101. PubMed ID: 329989
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective protection against the cytotoxicity of methotrexate and methotrexate-poly(lysine) by thiamine pyrophosphate, heparin and leucovorin.
    Shen WC; Ryser HJ
    Life Sci; 1981 Mar; 28(11):1209-14. PubMed ID: 6971979
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
    Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
    Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Method for determination of methotrexate in biological materials].
    Mori P; Salvadori C; Tedeschi R; Cocconi G
    Ric Clin Lab; 1979; 9(2 Suppl):27-34. PubMed ID: 317160
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
    Wiemann MC; Cummings FJ; Kaplan HG; Spremulli EN; Doolittle CH; Calabresi P
    Cancer Res; 1982 Sep; 42(9):3896-900. PubMed ID: 6980707
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid.
    Tonanont M; Inthasorn P; Boriboonhirunsarn D; Wongthiraporn W; Suphanit I
    J Med Assoc Thai; 2005 Oct; 88(10):1349-54. PubMed ID: 16519378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semisolid medium.
    Nederbragt H; Uitendaal MP; van der Grint L; Leyva A; Pinedo HM
    Cancer Res; 1981 Mar; 41(3):1193-8. PubMed ID: 6970074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucovorin and maximum tolerated dose toxicity of methotrexate in rats.
    Fuskevåg OM; Kristiansen C; Lindal S; Aarbakke J
    Pediatr Hematol Oncol; 2000 Dec; 17(8):651-8. PubMed ID: 11127396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of methotrexate toxicity in mice by a calcium salt of citrovorum factor and related compounds.
    Temple C; Rose JD; Laster WR; Montgomery JA
    Cancer Treat Rep; 1981; 65(11-12):1117-9. PubMed ID: 6975166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine.
    Bogyo D; Mihich E
    Cancer Res; 1980 Mar; 40(3):650-4. PubMed ID: 6970615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.